Recent comparative studies between CIS (IFN-γ+TNF treatment) and therapy-induced senescence (TIS, doxorubicin/palbociclib treatment) in melanoma models revealed that all treatments induced stable growth arrest and boosted SA-β-gal activity, with all except palbociclib significantly promoting p21 upregulation. The gene discussed is IFNG; the disease is melanoma.